New hope for BRCA-Linked breast cancer: targeted drug talazoparib under study

NCT ID NCT03990896

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug talazoparib (Talzenna) in 30 people with metastatic breast cancer that has spread beyond the breast. The cancer must have a specific BRCA gene mutation found only in the tumor (not inherited). Talazoparib works by blocking proteins that help repair DNA in cancer cells, which may cause the cells to die. The study measures how long the cancer stays under control and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talazoparib (Talzenna), a PARP inhibitor drug
What this could lead to: If successful, this could provide a targeted treatment option for people with metastatic breast cancer who have BRCA mutations in their tumor cells, potentially slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not work for all patients, and side effects like fatigue or nausea are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Emory University Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States
UCSF Medical Center-Mission Bay/Benioff Children's Hospital
RECRUITING

San Francisco, California, 94143, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232-6307, United States
Weill Cornell Medicine
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.